- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2025–2030 · program · P01
Project 3 - INSM1, A Candidate Therapeutic Target in High-Grade Neuroendocrine Carcinomas
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · program · P01
Administrative Core
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · program · P01
Project 1 - Epigenetic Control of Normal and Malignant Neuroendocrine Differentiation
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · program · P01
Project 2 - Epigenetic Drivers of Lineage Plasticity in Lung Cancer
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · fellowship · Postdoctoral Fellowship
Regulatory Mechanisms of Mitochondrial Cristae Formation Modulating Thermogenic Function
Jee Hyung Sohn · Dana-Farber Cancer Institute · funded by American Heart Association
2024–2027 · award
Targeting cancer-associated aberrant RNA to treat metastatic melanoma
Megan Insco · Dana-Farber Cancer Institute · funded by Melanoma Research Alliance
2024–2027 · grant · MRP
Data-Driven Biomarker-Informed Decision Analytics in Melanoma: Improving Efficacy and Reducing Toxicity of Immune Checkpoint Blockade
Alexander Gusev · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · research · R01
A multi-level examination of the influences of racism on cancer pain equity
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · PRCRP
Overcoming Rebound Growth of Pediatric Low-Grade Gliomas Following MAPK Pathway Inhibition
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · research · R01
Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · grant · PCRP
Dissection of Molecular Associations of Response to Neoadjuvant Antiandrogen Therapies in High-Risk Localized Prostate Cancer
Alok Tewari · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · award
Clinical Research Professor
Ann Partridge · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2026 · award
Revealing determinants of LINE-1 retrotransposition outcomes
Cheuk-Ting Law · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2027 · fellowship · Pew Biomedical Scholars
Pew Biomedical Scholar: Evanna Mills (2024)
Evanna Mills · Dana-Farber Cancer Institute · funded by Pew Charitable Trusts
2024 · research · Investigator Profile
Edward Chouchani — HHMI Investigator Profile (2024-Present)
Edward Chouchani · Dana-Farber Cancer Institute · funded by Howard Hughes Medical Institute
2024–2031 · research · R35
Mechanisms Driving the Rapid Evolution of Cancer Genomes
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · award
Interrogating the role of CD27-CD8+ T cells in immunotherapy responses
Frank Hodi · Dana-Farber Cancer Institute · funded by Melanoma Research Alliance
2024–2028 · grant · PRCRP
Investigation of a Multicancer Early Detection Test in a High-Risk Military Population
Catherine Marinac · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024 · fellowship · Pew Biomedical Scholars Program
Evanna Mills — Pew Biomedical Scholar (2024)
Evanna Mills · Dana-Farber Cancer Institute · funded by Pew Charitable Trusts
2024 · research · R03
The role of the mesenchymal niche in intestinal crypt fission
Neil Mccarthy · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · research · R61
New Chemical Tools for Covalent Drug Discovery
Justin Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · research · R21
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · grant · KCRP
Mechanistic Study of ccRCC Tumor Suppressor BAP1
Dongli Yu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2026 · career development · K99
Dissecting the Role of Germline Genetics in RAS-Driven Cancers
Ryan Lewis Collins · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · career development · K08
Integrating pain-CBT into an mHealth analgesic support intervention for patients withchronic pain from advanced cancers
Desiree R Hilton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors
Rachel Ann Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · grant · PRCRP
A Randomized Phase 2 Trial Evaluating the Novel PI3KD Inhibitor Roginolisib with Venetoclax/Rituximab for the Treatment of Relapsed CLL Patients
Jennifer Brown · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · career development · K08
Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia
Emily Heikamp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
Myeloma multidimensional precancer atlas
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · research · R21
Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors
Sharon L. Bober · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Survival Data Analysis using general censoring-free incident rate
Hajime Uno · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy
Derin B Keskin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · grant · MRP
Data-Driven Biomarker-Informed Decision Analytics in Melanoma: Improving Efficacy and Reducing Toxicity of Immune Checkpoint Blockade
David Liu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2026 · award
Discovery of new cyclic nucleotide immune receptors in human innate immunity
Sonomi Yamaguchi · Dana-Farber Cancer Institute · funded by Human Frontier Science Program
2024–2025 · award
Preparing a novel cytotoxic CD4+ T cell approach for clinical trial in patients with refractory B-cell malignancies
Baochun Zhang · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2027 · cooperative agreement · U34
Distance-based Exercise to preserve Function and prevENt Disability (DEFEND)
Jennifer A. Ligibel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · research · R21
In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R37
HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies
Oreofe Olukemi Odejide · Dana-Farber Cancer Institute · funded by National Institutes of Health
